Lipoprotein(a) in clinical practice: From genetic risk assessment to therapeutic silencing
World Journal of Translational Medicine · 28.11.2026 · 12 (4)
DOI: 10.5528/wjtm.124606 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Translational Medicine, online erschienen am 28.11.2026. Verfasst von Lucas D Feliciano und 5 weiteren Autor:innen. Die Arbeit nennt 161 Literaturangaben.
Abstract (Originalsprache)
Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein particle increasingly recognized as an independent and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Its unique structure, composed of a low-density lipoprotein-like particle bound to apolipoprotein(a), confers both atherogenic and proinflammatory properties that distinguish it from other circulating lipoproteins. This review examines the molecular structure of Lp(a), its genetic determinants, and the mechanisms linking elevated Lp(a) levels to atherogenesis and vascular inflammation. We critically discuss the role of apolipoprotein(a) isoform variability, kringle domain polymorphisms, oxidized phospholipid transport, endothelial dysfunction, inflammatory signaling pathways, and thrombogenic pathways in mediating cardiovascular risk. In addition, we review current approaches for laboratory assessment and summarize emerging therapeutic strategies aimed at selectively lowering Lp(a), including antisense oligonucleotides and small interfering RNA-based therapies. Recent advances in molecular therapeutics have demonstrated substantial reductions in circulating Lp(a) concentrations, although definitive evidence regarding cardiovascular outcome benefits is still under investigation. A better understanding of Lp(a) biology and its inflammatory and atherogenic mechanisms may improve risk stratification and support the development of personalized preventive and therapeutic strategies in cardiovascular medicine.
Zitieren
APA
Feliciano, L. D., Freire, J. P. C., Lopes, C. F., Lima, P. H. M., Costa, J. M. C., & Melo, F. F. D. (2026). Lipoprotein(a) in clinical practice: From genetic risk assessment to therapeutic silencing. World Journal of Translational Medicine, 12(4). https://doi.org/10.5528/wjtm.124606
Vancouver
Feliciano LD, Freire JPC, Lopes CF, Lima PHM, Costa JMC, Melo FFD. Lipoprotein(a) in clinical practice: From genetic risk assessment to therapeutic silencing. World Journal of Translational Medicine. 2026;12(4). doi:10.5528/wjtm.124606
BibTeX
@article{Feliciano2026,
author = {Feliciano, Lucas D and Freire, João P C and Lopes, Caio F and Lima, Pedro H M and Costa, Juan M C and Melo, Fabrício Freire de},
title = {Lipoprotein(a) in clinical practice: From genetic risk assessment to therapeutic silencing},
journal = {World Journal of Translational Medicine},
year = {2026},
volume = {12},
number = {4},
doi = {10.5528/wjtm.124606}
}
EUVIMED